<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03767764</url>
  </required_header>
  <id_info>
    <org_study_id>CIR2017/024</org_study_id>
    <nct_id>NCT03767764</nct_id>
  </id_info>
  <brief_title>Yliver as a Test to Early Diagnose HCC</brief_title>
  <acronym>YliverDIAG</acronym>
  <official_title>Yliver as a Test to Early Diagnose Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cancer (HCC) is the second cause of death related to cancer worldwide, with about
      750,000 deaths from this cause in 2012. Although the early diagnosis of liver cancer
      increases the available treatment options, the methods currently used for screening are not
      sufficiently sensitive for this purpose.

      The investigators provide a high-performance and highly reliable in vitro platform that
      allows the identification and quantification of autoantibodies in serum for use as biomarkers
      of liver cancer, using an ELISA test (Yliver).

      The aim of the study is to demonstrate whether the Yliver test can be used as a biomarker for
      the early diagnosis of hepatocellular carcinoma with a collection of samples from 58 patients
      diagnosed with HCC, 42 cirrhosis, 40 normal controls and the inclusion of 25-50 patients with
      chronic liver disease without cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 27, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Yliver</measure>
    <time_frame>October 2018-February 2019</time_frame>
    <description>Titer of autoantibodies against alpha fetoprotein applying Taby Technology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AFP</measure>
    <time_frame>October 2018-February 2019</time_frame>
    <description>Levels of alpha fetoprotein in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound</measure>
    <time_frame>October 2018-February 2019</time_frame>
    <description>Results of the ultrasound examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAb AFP</measure>
    <time_frame>October 2018-February 2019</time_frame>
    <description>Titer of autoantibodies against alpha fetoprotein with standard protocol</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>HCC</arm_group_label>
    <description>Patients with diagnosis of Hepatocellular carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhosis</arm_group_label>
    <description>Patients with the diagnosis of cirrhosis who is following a screening program for diagnosis of HCC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic liver diseases</arm_group_label>
    <description>Patients with the diagnosis of Chronic liver diseases without cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Normal human serum from donors without liver disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Test Yliver</intervention_name>
    <description>Test Yliver is used to detect autoantibodies against alpha fetoprotein in serum by an ELISA technique</description>
    <arm_group_label>Chronic liver diseases</arm_group_label>
    <arm_group_label>Cirrhosis</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>HCC</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HCC: patients with HCC diagnosis Cirrhosis: patients with liver cirrhosis diagnosis Chronic
        liver disease: patients with chronic liver diasease without cirrhosis Control: normal human
        serum from donors without liver disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        EASL Clinical Practice Guidelines &amp; Practice Guidance by the American Association for the
        Study of Liver Diseases for diagnosis of HCC, liver cirrhosis, chronic hepatitis without
        cirrhosis

        Exclusion Criteria:

          -  Age under 18 years

          -  Very advanced disease (patient in a terminal state that is not indicated analytical
             determinations).

          -  Hepatic encephalopathy that prevents the correct understanding of informed consent.

          -  Refusal to carry out the determination or to sign the informed consent.

          -  Patients affected by another neoplastic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Corporacion Parc Taul√≠</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Juan Francisco Delgado de la Poza</investigator_full_name>
    <investigator_title>Senior Immunologist</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Tumor associated antigen</keyword>
  <keyword>Early diagnosis</keyword>
  <keyword>Autoantibodies</keyword>
  <keyword>Alpha fetoprotein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

